Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
Esther Kissling, Mariëtte Hooiveld, Virginia Martin, Iván Martínez‐Baz, Naoma William, Ana‐Maria Vilcu, Clara Mazagatos, Lisa Domegan, Simon de Lusignan, Adam Meijer, Ausenda Machado, Mia Brytting, Itziar Casado, Josie Murray, Sylvie Belhillil, Amparo Larrauri, Joan O’Donnell, Ruby S. M. Tsang, Marit de Lange, Ana Paula Rodrigues, Maximilian Rieß, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Jade Cogdale, Tessa Jansen, Raquel Guiomar, Theresa Enkirch, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela Rose, Marta Valenciano, I-MOVE-COVID-19 primary care study team
Abstract
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.